Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data

• Published in: Frontiers in immunology Vol. 15; p. 1346464
• Main Authors: Li, Kemin, Yin, Rutie
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2024
• Subjects: Adenocarcinoma; Carcinoma, Ovarian Epithelial; Female; high-grade serous adenocarcinoma of the ovary; Humans; Hypersensitivity; Ovarian Neoplasms - drug therapy; Platinum - adverse effects; platinum allergy; platinum desensitization therapy; platinum-sensitive recurrence; Prognosis; Retrospective Studies; platinum allergy; platinum desensitization therapy; platinum-sensitive recurrence; prognosis; high-grade serous adenocarcinoma of the ovary
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1346464

To examine the value of five-step platinum desensitization therapy in epithelial ovarian cancer. A retrospective study was conducted on the high-grade serous adenocarcinoma of the ovary (HGSAO) patients who developed a platinum allergy during treatment and received desensitization therapy between January, 2016 and December, 2020. The logistic-regression was adopted to analyze the relationship between platinum desensitization therapy and prognosis in HGSAO patients. 92 HGSAO patients were included in the study. Among these, 35 patients (38.0%) experienced mild allergic reactions, 51 (55.4%) experienced moderate allergic reactions, and 6 (6.5%) experienced severe allergic reactions. The desensitization therapy was successful in 86 patients (93.5%). Six patients had desensitization failure, of which five experienced severe allergic reactions during desensitization. The logistic-regression analysis revealed no significant correlation between platinum desensitization therapy and progression-free survival (PFS) or overall survival (OS) of patients ( < 0.05). However, the subgroup analysis demonstrated that the success or failure of platinum desensitization therapy significantly impacted the OS of patients who were platinum-sensitive recurrence. The patients who had successful desensitization therapy had a superior OS. Five-step platinum desensitization therapy has potential application value in patients who were platinum-sensitive recurrence after first-line treatment but may bear the risk of severe allergic reactions.